Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04520932 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Pancreatic Radiofrequency Under High Echo-endoscopy in the Management of Pancreatic Neuroendocrine Tumors

Study acronym: RFANET
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

  1. Site contact updatedv5
  2. 2 versions Re-verified since Jan 5, 2022, no change to tracked fieldsv3-v4
  3. Trial status: Not Yet Recruiting to Recruitingv2 Show 4 more changesShow less
    • Start date changed from estimate of Dec 20, 2020 to Mar 30, 2021
    • Study sites: 0 to 1
    • Primary completion date: Dec 20, 2026 to Apr 2027
    • Study completion date: Dec 20, 2030 to Apr 2031
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Pancreatic radiofrequency ablation (RFA) could therefore be an alternative to the monitoring of pancreatic neuroendocrine tumors (PNETs) and more particularly nonfunctioning PNETs (NF-PNETs), which is costly and anxiety-inducing for patients. To date, only a few small studies have evaluated this treatment and the results are encouraging. It appears necessary to consider a large-scale study to ensure the efficacy and low morbidity of pancreatic RFA applied to PNETs.
Trial Details
NCT Number NCT04520932
Lead Sponsor Institut Paoli-Calmettes
Conditions
(from sponsor)		 Neuroendocrine Tumor of Pancreas (Disorder), Neuroendocrine Tumor Grade 1
Related terms Adenoma, Islet Cell
Enrollment 82 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov